Fiscal Year Ending March 2026 Financial Summary [Japanese GAAP] (Consolidated)

Overview of Financial Results

For the fiscal year ending March 2026, consolidated net sales were JPY 284,492 million (down 1.2% YoY), operating income was JPY 6,779 million (down 9.1% YoY), ordinary income was JPY 7,897 million (down 5.3% YoY), and net income attributable to owners of parent was JPY 3,200 million (down 34.5% YoY). The primary cause of decreased profits was the recording of impairment losses. Sales declined slightly across pharmaceuticals, cosmetics, general merchandise, and general food divisions. The number of stores reached 386 (160 with pharmacies), including 6 new store openings and 4 new pharmacy attachments. The equity ratio stood at 58.0%, up 0.7 points from the previous period, maintaining sound financial health.

Dividends and Future Outlook

The year-end dividend for the fiscal year ending June 2026 is planned at JPY 100, consisting of a regular dividend of JPY 80 plus a 65th anniversary commemorative dividend of JPY 20. For the next fiscal year ending March 2027, an interim dividend will be introduced, with an annual dividend forecasted at JPY 100 (interim JPY 50, year-end JPY 50). Earnings guidance for fiscal year March 2027 anticipates net sales of JPY 285 billion, operating income of JPY 5.1 billion, ordinary income of JPY 6.0 billion, and net income attributable to owners of parent of JPY 3.0 billion. The company plans to respond to changes in the business environment by promoting systemization and mechanization and strengthening specialization.